Press Releases
Cobra Bio Secures $3.3 Million to Develop DNA Vaccine Against COVID-19
U.K.-based Cobra Biologics and noted medical university the Karolinska Institute, which is based in Sweden, secured millions in emergency funding from Horizon 2020 to support research and development and an eventual Phase I clinical trial testing of a DNA...
Press Releases
GigaGen Works to Develop Passive, Convalescent COVID-19 Therapy
GigaGen is developing a recombinant polyclonal antibody therapy (rCIG) to treat COVID-19. First uses are envisioned as treatments for severely ill coronavirus patients and individuals at high risk of contracting the disease, including healthcare professionals.
“We are working toward an...
Press Releases
ideaPoint and WideTrial Launch Global Expanded Access Platform for COVID-19 Medicines
Anaqua’s ideaPoint, a provider of medical affairs and innovation management solutions, announced a strategic partnership with clinical data company WideTrial to facilitate greater access to investigational medicines for physicians and patients dealing with COVID-19 worldwide.
The project’s objective is to...
Press Releases
Abbott Launches Molecular Point-of-Care Test to Detect Novel Coronavirus in as Little as Five Minutes
Abbott announced that the U.S. FDA has issued Emergency Use Authorization (EUA) for the fastest available molecular point-of-care test for the detection of novel coronavirus (COVID-19), delivering positive results in as little as five minutes and negative results in...
Press Releases
Bora strengthens business development team to support US growth
Bora Pharmaceuticals, a full-service contract development and manufacturing organization (CDMO) which specializes in immediate and modified release oral solids and packaging, has announced the appointment of Mr. Lonnie Barish, MBA as Vice President of Business Development and Marketing.
Adding more...
Drug Research
Destroying DNA to Save the Genome – Study Offers New Insights into Sepsis and its Treatment
Sepsis is a life-threatening condition that kills millions annually; it is poorly understood and has no specific treatment. Now, researchers from Tata Memorial Centre, India, led by Prof. Dr Indraneel Mittra, have uncovered an important molecular mechanism underlying different...
Drug Research
C2 PHARMA Opens Government and Research Access to Safety Stock of DIGOXIN API for Use in Potential COVID-19 Combination Treatment
C2 PHARMA s.a.r.l. (C2P), a Luxembourg-based phytochemical and chemical pharmaceutical manufacturing and distribution group, is announcing that they will open access to safety stocks of the active pharmaceutical ingredient (API), Digoxin. In early March, the API was listed for...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read